The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Screening of Infants and Mortality Due to Neuroblastoma
Open accessAbstract
BACKGROUND: Neuroblastoma, the most common extracranial solid tumor that occurs in early childhood, can be identified in the preclinical stages by the detection of catecholamines in the urine. However, it is unknown whether routine screening for neuroblastoma reduces mortality due to this disease. METHODS: Through their parents, we offered screening for neuroblastoma at three weeks and six months of age to all 476,654 children born in the province of Quebec, Canada, during a five-year period (May 1, 1989, through April 30, 1994). The participation rate was 92 percent. The rate of death due to neuroblastoma was determined and compared with the rates in several unscreened control populations born during the same period. RESULTS: Among children younger than eight years of age in the Quebec cohort, there were 22 deaths due to neuroblastoma; the cumulative (+/-SE) mortality rate due to neuroblastoma was 4.78+/-1.14 per 100,000 children over a period of nine years. The standardized incidence ratios for death due to neuroblastoma for the Quebec cohort were 1.11 (95 percent confidence interval, 0.64 to 1.92) as compared with a control group in Ontario, Canada; 0.90 (95 percent confidence interval, 0.48 to 1.70) as compared with a control group in Minnesota; 1.40 (95 percent confidence interval, 0.81 to 2.41) as compared with a control group in Florida; and 0.96 (95 percent confidence interval, 0.56 to 1.66) as compared with a control group in the Greater Delaware Valley. The standardized mortality ratio for the Quebec cohort as compared with the rest of Canada was 1.39 (95 percent confidence interval, 0.85 to 2.30); the odds ratio for the comparison with a cohort born in Quebec before the screening program began was 0.98 (95 percent confidence interval, 0.54 to 1.77). CONCLUSIONS: Screening infants for neuroblastoma does not appear to reduce mortality due to this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
US Department of Health and Human Services; National Cancer Institute (1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,947
Neuroblastoma Screening at One Year of Age
Schilling, F. H., Spix, C., Berthold, F., Erttmann, R., Fehse, N., Hero, B., Klein, G., Sander, J., Schwarz, K., Treuner, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012277 · Cited by 464
A population-based study of the usefulness of screening for neuroblastoma
Woods, W. G., Tuchman, M., Robison, L. L., Bernstein, M., Leclerc, J.-M., Brisson, L. C., Brossard, J., Hill, G., Shuster, J., Luepker, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)06020-5 · Cited by 231
Self-citationRoss, J. A., Severson, R. K., Pollock, B. H., & Robison, L. L. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960101)77:1<201::aid-cncr32>3.0.co;2-7 · Cited by 168
Self-citationMASS SCREENING FOR NEUROBLASTOMA IN INFANTS IN JAPAN
Sawada, T., Nakata, T., Takasugi, N., Maeda, K., Hanawa, Y., Shimizu, K., Hirayama, M., Takeda, T., Mori, T., Koide, R., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90311-8 · Cited by 162
Molecular Basis of Clinical Heterogeneity in Neuroblastoma
Brodeur, G. M., & Nakagawara, A. (1992) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199205000-00004 · Cited by 155
A population-based study of neuroblastoma incidence, survival, and mortality in North America.
Bernstein, M. L., Leclerc, J., Bunin, G. R., Brisson, L., Robison, L. L., Shuster, J. J., Byrne, T. D., Gregory, D., Hill, G., & Dougherty, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.323 · Cited by 140
Self-citationIncidence of Childhood Cancer: Experience of a Decade in a Population-Based Registry 2
Shira Kramer, P. D. 4., Meadows, A. T., Patricia Jarrett, B. A., & Audrey E. Evans, M. D. (1983) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/70.1.49 · Cited by 127
BIOLOGY AND TREATMENT OF NEUROBLASTOMA
Castleberry, R. P. (1997) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70537-x · Cited by 112
Cited by
Neuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Welch, H. G., & Black, W. C. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq099 · Cited by 1,599
Etzioni, R., Urban, N., Ramsey, S., McIntosh, M., Schwartz, S., Reid, B., Radich, J., Anderson, G., & Hartwell, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1041 · Cited by 1,155
Neuroblastoma: Biology, Prognosis, and Treatment
Park, J. R., Eggert, A., & Caron, H. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.011 · Cited by 620
Computed Tomography Screening and Lung Cancer Outcomes
Bach, P. B. (2007) · JAMA · doi:10.1001/jama.297.9.953 · Cited by 567
Rethinking Screening for Breast Cancer and Prostate Cancer
Esserman, L. (2009) · JAMA · doi:10.1001/jama.2009.1498 · Cited by 516
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
Esserman, L. J., Thompson, I. M., Reid, B., Nelson, P., Ransohoff, D. F., Welch, H. G., Hwang, S., Berry, D. A., Kinzler, K. W., Black, W. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70598-9 · Cited by 501
Neuroblastoma Screening at One Year of Age
Schilling, F. H., Spix, C., Berthold, F., Erttmann, R., Fehse, N., Hero, B., Klein, G., Sander, J., Schwarz, K., Treuner, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012277 · Cited by 464
Overview and recent advances in the treatment of neuroblastoma
Whittle, S. B., Smith, V., Doherty, E., Zhao, S., McCarty, S., & Zage, P. E. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285230 · Cited by 394
Irwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
A mechanistic classification of clinical phenotypes in neuroblastoma
Ackermann, S., Cartolano, M., Hero, B., Welte, A., Kahlert, Y., Roderwieser, A., Bartenhagen, C., Walter, E., Gecht, J., Kerschke, L., et al. (2018) · Science · doi:10.1126/science.aat6768 · Cited by 335
Skin biopsy rates and incidence of melanoma: population based ecological study
Welch, H. G., Woloshin, S., & Schwartz, L. M. (2005) · BMJ · doi:10.1136/bmj.38516.649537.e0 · Cited by 330
Neuroblastoma: clinical and biological approach to risk stratification and treatment
Tolbert, V. P., & Matthay, K. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2821-2 · Cited by 304
Mechanisms of neuroblastoma regression
Brodeur, G. M., & Bagatell, R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.168 · Cited by 284
Updates in Diagnosis, Management, and Treatment of Neuroblastoma
Swift, C. C., Eklund, M. J., Kraveka, J. M., & Alazraki, A. L. (2018) · RadioGraphics · doi:10.1148/rg.2018170132 · Cited by 279
Prognostic Impact of Gene Expression–Based Classification for Neuroblastoma
Oberthuer, A., Hero, B., Berthold, F., Juraeva, D., Faldum, A., Kahlert, Y., Asgharzadeh, S., Seeger, R., Scaruffi, P., Tonini, G. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3367 · Cited by 135
Gaps in the Evidence for Well-Child Care: A Challenge to Our Profession
Moyer, V. A., & Butler, M. (2004) · Pediatrics · doi:10.1542/peds.2004-1076 · Cited by 109
Cancer Progress and Priorities: Childhood Cancer
Lupo, P. J., & Spector, L. G. (2020) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0941 · Cited by 91
Conceptualizing overdiagnosis in cancer screening
Marcus, P. M., Prorok, P. C., Miller, A. B., DeVoto, E. J., & Kramer, B. S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv014 · Cited by 90
Metadata
- Authors
- Woods, W. G., Gao, R.-N., Shuster, J. J., Robison, L. L., Bernstein, M., Weitzman, S., Bunin, G., Levy, I., Brossard, J., Dougherty, G., Tuchman, M., & Lemieux, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-04-04
- Volume
- 346
- Issue
- 14
- Pages
- 1041-1046
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1995294036
- Cited by
- 356
- References
- 12
- FWCI
- 16.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.